News
31.05.2016

We at Cromos Pharma are always interested in what makes a sponsor choose a certain CRO

In order to get a better understanding of this question we have conducted a survey where we asked industry professionals about their vision of a "perfect CRO". Our team would like to express sincere gratitude to all the participants of the survey whose responses we greatly appreciate.

Below you can find the top-line results of the survey. A more detailed analysis of the collected data will soon be published in an industry related journal.

Respondents’ profiles

A total of 122 participants completed the questionnaire. The majority of respondents listed pharmaceutical companies as their place of work (81.8%), 13.6% listed biotech companies and 4.6% indicated that they belonged to other types of organizations (e.g. academic research organizations).

As represented in the graph below, the largest group of respondents (25.7%) identified themselves as employees of large pharma (1000-5000 employees), followed by representatives of small companies (1-50 employees) – 19.1%.

At the same time, 47.6% of respondents indicated that their companies initiate between 1 and 5 trials per year.

*number of studies significantly varies from year to year

When asked to rate Outside of US (OUS) clinical trial locations, more than 70% of respondents identified former Soviet bloc countries as the most attractive clinical research region, followed by Central, Eastern Europe and Asia, which jointly took around 25% of the votes. The least favorite locations included Middle East, Africa and Australia (less than 5% of replies).

CRO selection criteria

Ranked in order of importance, the following criteria were identified as pertinent when choosing a CRO:

1. Reasonable cost, transparent budget proposal
2. Performance during bidding process (understanding of project details, response times, suggestions on study optimization)
3. CRO experience (staff experience in a given therapeutic area)
4. CRO reputation, industry recommendations

The least important criteria included:

1. Location of headquarters (more than 50% of respondents indicated that it did not influence their CRO selection)
2. CRO size
3. Breadth of geographical coverage.

According to the majority of replies, a perfect CRO is a mid-sized organization that covers several countries (almost 50% of responses).

Answers Choices

Responses, %

Global, covering all countries the study may be conducted in

21.3

Mid-sized, covering several countries

47.8

Small, covering 1-2 countries where the study is being planned

30.9

When asked about the average duration of their relationships with CROs, the greatest number of respondents preferred to work with a reliable and known partner.

Answer Choices

Responses, %

A new CRO is selected for each project

16.0

We work with one partner on average of 2-4 years

47.8

We have a long-standing relationship that lasts more than 5 years

36.2

The graph below demonstrates that CRO’s therapeutic specialization tends to be of great importance to respondents. However this appears to be critical only in certain therapeutic fields (e.g. Dermatology, Ophthalmology).

Question: Do you prefer to work with a specialized CRO (i.e. therapeutically focused CRO)?

When asked about the most crucial factor in choosing a certain CRO, the majority of respondents emphasized past experience with this CRO. It is also worth noting that persuasive skills of CRO’s team members at bid defenses had no effect on CRO selection.

When asked about CRA's education, the majority of respondents rated medical background as non-critical, but preferable (55% of respondents).

Answers Choices

Responses, %

Medical background is one of the key factors when choosing a study team

20.3

Medical education is preferable, but is not critical

55.2

It's experience in clinical trials that we care about

24.5

We hope that this snapshot of our survey results will add to your understanding of the current trends in CRO selection. If you are interested in receiving a copy of an upcoming publication with complete analysis of the collected data, please email us at: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Other News:
news

Data management and Biostatistics solutions to ensure the quality of your data

Effective data management and biostatistics are crucial for producing high quality data for successful clinical trials. At Cromos Pharma our expert data management and biostatistics team provides innovative solutions to ensure transparency, data integrity and quality of your data.
23.03.2021
news

Cromos Pharma appoints new Business Development Director for Central and Eastern Europe

At Cromos Pharma we are constantly growing and developing expanding our horizons and building our capacity to deliver innovative clinical trials solutions across our global network of operations. Therefore, we are delighted to announce the appointment of Nataliya Artyushenko as our new Business Development Director for Central and Eastern Europe.
21.03.2021
news

Reasons to choose Ukraine as the location for your next clinical trial

Ukraine, the eight largest European country by population, is an attractive location for sponsors conducting clinical research for a number of key reasons. Cromos Pharma has been successfully managing clinical trials in Ukraine since 2006. This article looks at just some of the benefits of locating your next study here.

16.03.2021
news

Cromos Pharma charting new territories as it looks east to Uzbekistan

Cromos Pharma is continuously developing and looking to explore new territories when it comes to clinical research. In line with this spirit of discovery, we will be shortly commencing a new project in Uzbekistan supporting a study being conducted by the Swiss Tropical and Public Health Institute. 

11.03.2021
news

IWD2021: Championing Women making healthcare breakthroughs

March 8th is International Women’s day, a global day of celebration of the social, political cultural and economic achievements of women. It is also a day for promoting the goal of greater gender parity across all sections of society. At Cromos Pharma, we are using this day to celebrate just a few of the many trailblazing women in healthcare.
08.03.2021
news

Cromos CEO outlines advantages of Central and Eastern Europe for clinical trials

Thinking about Eastern Europe as a venue for your clinical trial? Cromos Pharma CEO Vlad Bogin outlines some of the advantages in this new interview.
04.03.2021
news

Rare diseases and drug development

The World Economic Forum estimates that 475 million people worldwide are affected by a rare disease. To mark World Rare Disease Day (28 February 2021), in this article Stephanie Finnegan, Cromos Pharma’s COO, explores the opportunities and challenges for rare disease drug development.
26.02.2021
news

Key factors to consider for rare disease/orphan drug development

To mark World Rare Disease Day (28th February 2021), Cromos Pharma's Head of Start-Up outlines some of the key factors to consider for rare disease/orphan drug clinical trials.
26.02.2021
news

Connect with us at DIA Europe and BIO-Europe this March

Cromos Pharma is delighted to be taking part in the upcoming DIA Europe conference (15 – 19 March 2021) and BIO-Europe Spring (22-25 March 2021).

 

15.02.2021
news

International Women and Girls in Science Day

February 11th is International Women and Girls in Science Day. A joint UNESCO and UN-Women initiative, it aims to promote the role of #WomenInScience and to challenge some of the barriers to girls pursuing a career in science.

11.02.2021
news

Top 5 reasons to locate your next clinical trial in Hungary

Discover some of the reasons why you should consider Hungary as a location for your next clinical trial.
09.02.2021
news

Cromos Pharma offers EU Legal Representative Service

Are you a sponsor seeking to conduct clinical trials in the European Union but do not have a registered office in the European Economic AreaIf so, in order to comply with the European Union Clinical Trial Directive, you are required to work with a Legal Representative registered in an EEA country.

04.02.2021
news

World Cancer Day 2021: Cromos Pharma is committed to supporting clinical research to make cancer breakthroughs

Each 4th February, #WorldCancerDay aims to raise awareness of the global personal, social and economic burden of cancer. World Cancer Day was established in Paris at the first World Cancer Summit in 2000.

 


04.02.2021
news

European Medicines Agency: Approvals January 2021

The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) recommended 13 new medications for approval and three therapeutic indication extensions in its January 2021 meeting.
31.01.2021
news

Upcoming EU drug/device legislation: What you need to know

Zsolt Kocsis, Cromos Pharma's Head of EU Operations explores some of the upcoming changes to EU legislation in relation to drug development and medical devices. 
25.01.2021
news

Reaping the benefits of a Euro-Australian collaboration for biotechs: save on costs and time

Cromos Pharma CEO Dr Vlad Bogin is joined by Avance Clinical's CEO Yvonne Lungershausen to discuss some of the benefits available to biotechs by availing of a joint initiative that combines Australian tax benefits for clinical research with exceptional patient recruitment and retention in Eastern European markets.
24.01.2021
news

Clinical trials in the time of COVID: Risks, mitigation and lessons learned

Clinical trials in the time of COVID: Risks, mitigation and lessons learned presented by Stephanie Finnegan, COO Cromos PharmaIn this presentation she looks at risks, how to mitigate crisis management, and what the sector has learned since being forced into some major changes due to COVID-19. 

24.01.2021
news

Clinical trials: how to enroll on time, stay on budget and not compromise data quality

Stephanie Finnegan, COO of Cromos Pharma delivers key insights into how to maintain study and data integrity when facing cost and time constraints. When time and money is of the essence how can you achieve patient recruitment targets? 
23.01.2021
news

Global vaccine rollout underway as COVID-19 cases surge

As 2021 begins, many countries are grappling with a renewed surge of COVID-19 infections necessitating further public health restrictions putting more pressure on health systems, societies and global economies.  The task of rolling out approved vaccines is increasingly urgent. Almost 16 million doses of COVID-19 vaccines have been administered to date in 37 countries worldwide according to data compiled by Bloomberg ( updated 7 Jan 2021). 

07.01.2021
news

JP Morgan Healthcare Conference: Virtual Booth and Daily Presentations

We have been meeting you at the JP Morgan Healthcare Conference for the past 11 years and there is no way we are going to break with this tradition. Meet us at the CROMOS PHARMA VIRTUAL BOOTH January 11th through 14th from 8 am to 5 pm(PST). Learn about some of the most vital issues in clinical research by attending our daily presentations or stop by anytime for a chat.


01.01.2021
news

Seasons Greetings from Cromos Pharma

Seasons Greetings from everyone at Cromos Pharma. Watch our holiday video here>>
22.12.2020
news

Watch: The benefits of Cromos Pharma and Avance Clinical's biotech initiative

In October we launched an exciting collaboration with Avance Clinical to offer biotechs a scalable clinical trials solution. The collaboration allows biotechs to quickly start their pre-IND early phase studies in Australia, then expand to Central/Eastern Europe to access the large patient populations for their Phase 2 and 3 studies. In this new video you can learn more about the benefits of this initiative.


08.12.2020
news

World AIDS Day 2020: Remarkable progress but the fight continues

Tuesday 1 December marked World AIDS Day 2020. Although throughout this year our focus has been on the coronavirus pandemic, World AIDS Day is an opportunity to reflect on another pandemic where a virus passed from animals to humans with devastating consequences. To date 77 million people worldwide have been infected with HIV. In spite of innovative new treatments 35 million people have died from the virus. 

01.12.2020
news

Thanksgiving Greetings

Thanksgiving Greetings from everyone at Cromos Pharma. Watch our video here.
20.11.2020
news

World Pancreatic Cancer Awareness Day 2020

Thursday 19 November 2020 is World Pancreatic Cancer Awareness Day. Here at Cromos Pharma we are proud to play our part in supporting clinical trials aimed at finding better treatments for pancreatic cancers. 

19.11.2020
news

FDA Offers Guidance to Enhance Diversity in Clinical Trials

The FDA released a statement (9 November 2020) outlining its commitment to promoting greater diversity in medical product development and issuing a new guidance document outlining the agency's thinking on encouraging greater inclusivity “Enhancing the Diversity of Clinical Trial Populations--Eligibility Criteria, Enrollment Practices, and Trial Designs,”
12.11.2020
news

Cromos Pharma and Avance Clinical share details of innovative collaboration at BIO-Europe 2020

Cromos Pharma and Avance Clinical announced details of their innovative collaboration to offer biotechs scalable clinical trial solutions at BIO-Europe 2020.
28.10.2020
news

Orphan Drugs Market to Reach USD 340.84 Billion by 2027

The global orphan drugs market size is projected to reach USD 340.84 billion by the end of 2027. Increasing number of regulatory approvals will have a positive impact on the growth of the overall market in the coming years according to a new report from Fortune Business Insights
26.10.2020
news

Cromos Pharma and Avance Clinical launch scalable clinical trial solution for biotech

Cromos Pharma is delighted to announce a new collaboration with Avance Clinical providing a scalable clinical trial solution for biotech.
08.10.2020
news

Video: Cromos Pharma and Avance Clinical Collaboration

Cromos Pharma and Avance Clinical are joining forces to offer a scalable clinical trial solution for biotechs. Watch the video to find out more>>
08.10.2020
news

Alzheimer's Awareness Month: Q&A with Dr Sabina Brennan

September is World Alzheimer’s Month. Alzheimer’s Disease (AD) is the most well-known form of dementia. Dementia is the collective name for progressive brain conditions affecting memory, thinking, behavior and emotions. Dementia affects almost 50 million people worldwide. While aging is a major risk factor for dementia, it also affects people under 65 years. To mark Alzheimer’s Awareness Month (Sept 2020) we sat down with leading psychologist, neuroscientist and best-selling author Dr Sabina Brennan. Dr Brennan is a brain health expert who has advised Irish and UK governments on policies relating to aging and dementia.  She is the Irish national representative on the Medical and Scientific Advisory Panel for Alzheimer’s Disease International.
28.09.2020
news

Watch Webinar: Where in the world should I locate my pivotal clinical trial?

If you missed the live webinar “Where in the world should I locate my pivotal clinical trial?” you can now watch the recording by clicking hereThe webinar hosted by the Society of Physician Entrepreneurs (SoPE) and Workforce Genetics features Cromos Pharma's CEO Vlad Bogin, M.D, FACP. 


24.09.2020
news

Watch our video: Navigating an era of uncertainty

We are pleased to share with you our new video Cromos Pharma: Helping to navigate an era of uncertainty.

02.09.2020
news

Webinar: Where in the world should I locate my pivotal clinical trial?

01.09.2020
news

EU cancer estimates for 2020 reveal 2.7 million new cases

The European Joint Research Council released its 2020 burden of cancer estimates on 22 July, 2020. The report revealed The cancer burden is estimated to have risen to 2.7 million new cases (all types, excluding non-melanoma skin cancer) and 1.3 million deaths in 2020. Female breast cancer remains the most commonly diagnosed.
26.07.2020